Share of Depomed (DEPO +10.6%) try to recoup some of yesterday's post-earnings-report loss. Prices are off ~10% from the intraday high of $12.83 but still cling to a decent gain on modestly higher volume.
Consensus estimates for Q2 and Q3 are EPS of $0.03 on revenues of $40M and $0.10/share on revenues of $48.4M, respectively.
Consensus views for 2014 and 2015 are EPS of $0.31 on revenues of $208.1M and EPS of $.20 on revenues of $184M, respectively.
175 mutual funds have positions, up from 134 a year earlier.